Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: PaxMedica Therapeutics and Medicenna Therapeutics Corp, one private company, Vaccitech Limited, and on one not-for-profit company, Medicines 360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.
What is Karen A. Dawes' net worth?
The estimated net worth of Karen A. Dawes is at least $12.62 million as of February 27th, 2024. Ms. Dawes owns 87,367 shares of Repligen stock worth more than $12,621,037 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Dawes may own. Learn More about Karen A. Dawes' net worth.
How do I contact Karen A. Dawes?
Has Karen A. Dawes been buying or selling shares of Repligen?
Karen A. Dawes has not been actively trading shares of Repligen over the course of the past ninety days. Most recently, Karen A. Dawes sold 1,000 shares of the business's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a transaction totalling $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company's stock, valued at $16,892,409.45. Learn More on Karen A. Dawes' trading history.
Who are Repligen's active insiders?
Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (Executive Chair), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?
In the last year, Repligen insiders bought shares 2 times. They purchased a total of 3,615 shares worth more than $449,938.10. In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 72,325 shares worth more than $12,382,469.27. The most recent insider tranaction occured on September, 10th when Director Anthony Hunt sold 22,191 shares worth more than $3,225,905.67. Insiders at Repligen own 1.2% of the company.
Learn More about insider trades at Repligen. Information on this page was last updated on 9/10/2024.
